293 related articles for article (PubMed ID: 33017541)
1. Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers).
Yadav KS; Upadhya A; Misra A
Expert Opin Drug Deliv; 2021 Jan; 18(1):103-118. PubMed ID: 33017541
[TBL] [Abstract][Full Text] [Related]
2. Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review.
Ara N; Hafeez A
AAPS PharmSciTech; 2024 Feb; 25(3):47. PubMed ID: 38424367
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.
Majumder J; Minko T
Expert Opin Drug Deliv; 2021 Feb; 18(2):205-227. PubMed ID: 32969740
[TBL] [Abstract][Full Text] [Related]
4. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
5. α-Conotoxin ImI-modified polymeric micelles as potential nanocarriers for targeted docetaxel delivery to α7-nAChR overexpressed non-small cell lung cancer.
Mei D; Zhao L; Chen B; Zhang X; Wang X; Yu Z; Ni X; Zhang Q
Drug Deliv; 2018 Nov; 25(1):493-503. PubMed ID: 29426250
[TBL] [Abstract][Full Text] [Related]
6. Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC).
Patil SM; Sawant SS; Kunda NK
Int J Pharm; 2021 Sep; 607():121046. PubMed ID: 34450225
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation.
Huang WT; Larsson M; Wang YJ; Chiou SH; Lin HY; Liu DM
Mol Pharm; 2015 Apr; 12(4):1242-9. PubMed ID: 25760774
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
10. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
11. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy.
Kumar M; Jha A; Dr M; Mishra B
Expert Opin Drug Deliv; 2020 Oct; 17(10):1459-1472. PubMed ID: 32684002
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
13. Nanocarriers for cancer-targeted drug delivery.
Kumari P; Ghosh B; Biswas S
J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
[TBL] [Abstract][Full Text] [Related]
14. Combinational drug delivery using nanocarriers for breast cancer treatments: A review.
Olov N; Bagheri-Khoulenjani S; Mirzadeh H
J Biomed Mater Res A; 2018 Aug; 106(8):2272-2283. PubMed ID: 29577607
[TBL] [Abstract][Full Text] [Related]
15. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy.
Dinakar YH; Karole A; Parvez S; Jain V; Mudavath SL
Life Sci; 2022 Dec; 310():121133. PubMed ID: 36306866
[TBL] [Abstract][Full Text] [Related]
16. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
17. Nanocarrier functionalization strategies for targeted drug delivery in skin cancer therapy: current progress and upcoming challenges.
Di Filippo LD; de Paula MC; Duarte JL; de Paula GA; Frigieri I; Chorilli M
Expert Opin Drug Deliv; 2023 Jun; 20(6):831-849. PubMed ID: 37259517
[TBL] [Abstract][Full Text] [Related]
18. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
Koning GA; Krijger GC
Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
20. Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.
Yu XY; Jin X; Shou ZX
Drug Deliv; 2021 Dec; 28(1):1995-2010. PubMed ID: 34569401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
